1SaifMW.New developments in the treat ment of pancreatic cancer.Highlights from the "44th ASCO Annual Meeting"[J].JOP,2008,9(4):391-397.
2Jemal A,Siegel R,Ward E,et al.Cancer statistics,2009[J].CA Cancer J Clin,2009,59(4):225-249.
3Schnelldorfer T,Ware AL,Sarr MG,et al.Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma:is cure possible[J]Ann Surg,2008,247(3):456-462.
4Campbell P J,Yachida S,Mudie L J,et al.The patterns and dynamics of genomic instability in metastatic pancreatic cancer[J].Nature,2010,467(7319):1109-1113.
6Pingpank JF,Hoffman JP,Ross EA,et al.Effect of preoperative chemoradiotherapy on surgical margin status ofresected adenocarcinoma of the head of the pancreas[J].J Gastrointest Surg,2001,5(2):121-130.
7Micames C,Jowell PS,White R,et al.Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs.percutaneous FNA[J].Gastrointest Endosc,2003,58(5):690-695.
8Van Laethem JL,Hammel P,Momex F,et al.Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer:arandomized EORTC-40013-22012/FFCD9203/GERCOR phase Ⅱ study[J].J Clin Oncol,2010,28(29):4450-4456.
9Ueno H,Kosuge T,Matsuyama Y,et al.A randomised phase Ⅲ trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer:Japanese Stu dy Group of Adjuvant Therapy for Pancre atic Cancer[J].Br J Cancer,2009,101(6):908-915.
